StockWatch
·

BIOGEN INC. Q3 FY26 Results

BIIBQ3 FY26 Results
Filing
MetricValue ($ M)Q2 FY26Q3 FY25
Revenue2.8K2.5%10.6%
Total Income2.8K2.5%10.6%
Expenditure2.8K8.1%42.3%
PBT-9.00106.8%101.6%
Net Profit-20.60121.1%104.4%
OPM—
NPM-0.73%4.30pp19.14pp
EPS-0.14121.2%104.4%
View full financials

Biogen Reports Q3 2026 Results with 11% Revenue Growth

28 Oct 2026 · 28 Oct, 3:41 pm

Summary

Biogen announced third quarter 2026 financial results, with total revenue increasing 11% year-over-year to $2.8 billion. This growth was significantly boosted by the Growth Portfolio, which saw a 49% increase driven by acquired Apellis products. While GAAP diluted EPS was $(0.14) due to transaction costs, Non-GAAP diluted EPS stood at $2.62. The company raised its full-year 2026 Non-GAAP diluted EPS guidance, reflecting ongoing business strength and favorable Apellis dilution. Management highlighted the return to growth and the strength of the Growth Portfolio.

Key Highlights

  1. 1

    Biogen reported third quarter 2026 total revenue of $2.8 billion, an increase of 11% year-over-year.

  2. 2

    Growth Portfolio revenue reached $1.26 billion, up 49% year-over-year, driven by a strong contribution from acquired Apellis products.

  3. 3

    GAAP diluted EPS was $(0.14) due to transaction-related charges, while Non-GAAP diluted EPS was $2.62.

  4. 4

    The company is raising the lower end of its full year 2026 Non-GAAP diluted EPS guidance to $12.20 to $13.00.

  5. 5

    Third quarter results reflect strong operating performance from the legacy Apellis portfolio following successful integration.

  6. 6

    Total revenue for the nine months ended September 30, 2026, was $8.018 billion, an increase of 5.3% year-over-year.

Management Comments

C

Christopher A. Viehbacher

Our third quarter results demonstrate that Biogen has returned to growth. We’re seeing the strength of our Growth Portfolio – including the first full quarter of results from Apellis products – which helped drive double-digit revenue growth and an approximately 50% year-over-year increase from our growth products. With multiple Phase 3 readouts expected over the next 12 months, we are positioned to further strengthen our long-term growth profile and create sustainable value for patients and shareholders.

Informational and educational content only. Not investment advice.